AbbVie is a global biopharmaceutical company focused on prescription medicines for autoimmune diseases, neurological conditions, cancer, and aesthetics. The company's two core growth drivers are Skyrizi, a quarterly-injected biologic for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and Rinvoq, a once-daily oral JAK inhibitor approved across nine-plus autoimmune indications. Together, these two products generated approximately $25.9B in FY25 revenue, and AbbVie guides for over $31B in combined sales in 2026. AbbVie's older blockbuster, Humira, has been losing share to biosimilars since 2023 and is a declining contributor. AbbVie's neuroscience business includes Vraylar for schizophrenia and bipolar disorder, Botox Therapeutic for migraine and neurological conditions, oral migraine drugs Ubrelvy and Qulipta, and Vyalev for advanced Parkinson's disease. The aesthetics business, acquired through the 2020 Allergan deal, includes Botox Cosmetic and Juvederm fillers, both sold as cash-pay procedures directly to physician practices. AbbVie sells prescription products through major wholesalers and specialty pharmacies, and earns net revenue after rebates negotiated with payers and pharmacy benefit managers. AbbVie reinvests heavily in R&D and has executed over 30 business development deals since early 2024, targeting early-stage assets in immunology, oncology, and neuroscience to support growth into the 2030s. The company generates substantial free cash flow, which funds its dividend, debt repayment, and M&A.